The treatment of Graves' disease: Current views and controversies;Traitement de la maladie de Basedow : Problématiques actuelles

Presse Medicale

Volumn 40, Issue 12 PART 1, 2011, Pages 1155-1162

  Orgiazzi, Jacques ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; THYROTROPIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE; RADIOACTIVE IODINE;

AWARENESS; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; IATROGENIC DISEASE; PATIENT COUNSELING; PATIENT EDUCATION; QUALITY OF LIFE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; SMOKING; SMOKING CESSATION; THYROTROPIN BLOOD LEVEL; CONFLICT; DECISION MAKING; DRUG CONTRAINDICATION; ENDOCRINOLOGY; EVALUATION; FEMALE; METHODOLOGY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; THYROIDECTOMY; UTILIZATION REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTITHYROID AGENTS; CHOICE BEHAVIOR; DECISION MAKING; DISSENT AND DISPUTES; ENDOCRINOLOGY; FEMALE; GRAVES DISEASE; HUMANS; IODINE; IODINE RADIOISOTOPES; PREGNANCY; PREGNANCY COMPLICATIONS; THYROIDECTOMY;

EID: 84856151598     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.09.012     Document Type: Short Survey

References (31)

1. Orgiazzi J. Maladie de Basedow. La thyroïde 2001, Expansion scientifique française, Paris, p. 392-8. J. Leclère, J. Orgiazzi, B. Rousset, J.L. Schlienger, J.L. Wémeau (Eds.).
2. Leclère J., Orgiazzi J. Manifestations extrathyroïdiennes de la maladie de Basedow. La thyroïde 2001, Expansion scientifique française, Paris, p. 399-406. J. Leclère, J. Orgiazzi, B. Rousset, J.L. Schlienger, J.L. Wémeau (Eds.).
3. Neumann S., Gershengorn M.C. Small molecule TSHR agonists and antagonists. Ann Endocrinol (Paris) 2011, 72:74-76.
4. Lazarus J.H. Hyperthyroidism. Lancet 1997, 349:339-343.
5. Trzepacz P.T., Klein I., Roberts M., Greenhouse J., Levey G.S. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989, 87:558-561.
6. Orgiazzi J., Madec A.M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid 2002, 12:849-853.
7. Cooper D.S. Antithyroid drugs. N Engl J Med 2005, 352:905-917.
8. Laurberg P., Vestergaard H., Nielsen S., Christensen S.E., Seefeldt T., Helleberg K., et al. The sources of circulating 3,5,3'tri-iodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 2007, 92:2149-2156.
9. Cooper D.S. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003, 88:3474-3481.
10. Andersohn F., Konzen C., Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007, 146:657-665.
11. Bahn R.S., Burch H.S., Cooper D.S., Garber J.R., Greenlee C.M., Klein I.L., et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009, 19:673-674.
12. Cin M.O., Gursoy A., Morris Y., Aydintug O.T., Kamel N., Gullu S. Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. Int J Clin Pract 2009, 63:299-302.
13. Abraham P., Avenell A., Park C.M., Watson W.A., Bevan J.S. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endorinol 2005, 153:489-498.
14. Kahina B., Maiza J.C., Bennet A., Caron P. Thyrotoxicosis: adjunctive cholestyramine therapy. Presse Med 2010, 39:1217-1220.
15. Boelaert K., Syed A.A., Manji N., Sheppard M.C., Holder R.L., Gough S.C., et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf) 2009, 70:129-138.
16. Alexander E.K., Larsen P.R. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002, 87:1073-1077.
17. McDermott M.T., Kidd G.S., Dodson L.E., Hofeldt F.D. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med 1983, 75:353-359.
18. Walter M.A., Briel M., Christ-Crain M., Bonnema S.J., Connell J., Cooper D.S., et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007, 334:514.
19. Franklyn J.A., Sheppard M.C., Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005, 294:71-80.
20. Metso S., Auvinen A., Huhtala H., Salmi J., Oksala H., Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007, 109:1972-1979.
21. Lal G., Ituarte P., Kebebew E., Siperstein A., Duh Q.Y., Clark O.H. Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease?. Thyroid 2005, 15:569-574.
22. Nedrebo B.G., Holm P.I., Uhlving S., Sorheim J.I., Skeie S., Eide G.E., et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 2002, 147:583-589.
23. Allannic H., Fauchet R., Orgiazzi J., Madec A.M., Genetet B., Lorcy Y., et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990, 70:675-679.
24. Weetman A.P. Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission?. Nat Clin Pract Endocrinol Metab 2006, 2:2-3.
25. Cooper D.S. Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med 1985, 102:328-331.
26. Nayak B., Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006, 35:663-686.
27. Kaguelidou F., Alberti C., Castanet M., Guitteny M.A., Czernichow P., Léger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008, 93:3817-3826.
28. Read C.H., Tansey M.J., Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004, 89:4229-4233.
29. Rivkees S.A., Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 2007, 92:797-800.
30. Abraham-Nordling M., Törring O., Hamberger B., Lundell G., Tallstedt L., Calissendorff J., et al. Graves'disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005, 15:1279-1286.
31. Patel N.N., Abraham P., Buscombe J., Vanderpump M.P. The cost effectiveness of treatment modalities for thyrotoxicosis in a UK center. Thyroid 2006, 16:593-598.